Hepatic immunity

Hepatic immunity refers to the specialized and highly regulated immune system of the liver, which functions as a critical interface between the systemic circulation and the nutrient-rich, antigen-laden blood from the gastrointestinal tract [1, 10, 11]. Unlike most other organs, the healthy liver maintains a predominantly tolerogenic environment to prevent chronic inflammation from dietary and commensal bacterial antigens while remaining vigilant against pathogens and malignant cells [2, 9]. This complex system involves a unique repertoire of resident cells, including Kupffer cells (liver-resident macrophages), hepatic stellate cells, liver sinusoidal endothelial cells (LSECs), and a high concentration of innate-like lymphocytes such as Natural Killer (NK) and Natural Killer T (NKT) cells [5, 6, 13]. Dysregulation of hepatic immunity is a primary driver in various pathologies, ranging from viral and autoimmune hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma [4, 12]. Therapeutic strategies in drug development often focus on modulating specific components of this microenvironment, such as using immune checkpoint inhibitors to overcome tumor-induced immunosuppression or anti-inflammatory agents to curb autoimmune damage [3, 15, 16].

Other names

Liver immunityHepatic immune systemIntrahepatic immunityHepatic immune microenvironmentLiver immunology

Drugs targeting this system generally work by modulating the activity of specific immune cell populations, such as inhibiting immune checkpoints (PD-1/PD-L1), suppressing pro-inflammatory cytokine signaling, or boosting antiviral innate responses [1, 3, 8, 15].